Northwestern University scientists have uncovered a hidden molecular "control switch" inside a protein that helps the body ...
Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, ...
Myqorzo and Redemplo approved in ChinaApproval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia ...
CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026Planned milestones include pivotal dose selection, ...
LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of ...
A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...
Northwestern University scientists have uncovered a hidden molecular "control switch" inside a protein that helps the body ...
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndromeUnderscores Sanofi's long-term commitment to ...
Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 ...
Researchers are uncovering how disrupted glutamatergic synapses drive diverse forms of intellectual disability, revealing new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback